Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Gross Profit: 2014-2025

Historic Gross Profit for ImmunityBio (IBRX) over the last 12 years, with Sep 2025 value amounting to $31.9 million.

  • ImmunityBio's Gross Profit rose 422.17% to $31.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $82.2 million, marking a year-over-year increase of 1020.89%. This contributed to the annual value of $14.7 million for FY2024, which is 2270.58% up from last year.
  • According to the latest figures from Q3 2025, ImmunityBio's Gross Profit is $31.9 million, which was up 21.28% from $26.3 million recorded in Q2 2025.
  • ImmunityBio's 5-year Gross Profit high stood at $31.9 million for Q3 2025, and its period low was $14,000 during Q1 2022.
  • For the 3-year period, ImmunityBio's Gross Profit averaged around $8.2 million, with its median value being $1.0 million (2024).
  • Per our database at Business Quant, ImmunityBio's Gross Profit slumped by 89.93% in 2022 and then spiked by 41,047.50% in 2025.
  • Over the past 5 years, ImmunityBio's Gross Profit (Quarterly) stood at $390,000 in 2021, then tumbled by 81.28% to $73,000 in 2022, then spiked by 90.41% to $139,000 in 2023, then surged by 5,333.09% to $7.6 million in 2024, then soared by 422.17% to $31.9 million in 2025.
  • Its last three reported values are $31.9 million in Q3 2025, $26.3 million for Q2 2025, and $16.5 million during Q1 2025.